Small-molecule inhibition of the METTL3/METTL14 complex suppresses neuroblastoma tumor growth and promotes differentiation
Monica Pomaville(Children's Hospital of Philadelphia), Susan L. Cohn(Comer Children's Hospital)
Cited by 36
Related Papers
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial
|The Lancet Oncology|2019|341
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
|Clinical Cancer Research|2018|88